CVS Health Faces Ongoing Scrutiny from Florida Probe While Stock Trends Remain Under Pressure

CVS Health (NYSE: CVS) stock closed at $87.95 on October 7, 2026, marking a 1.76% gain that day, though it remains down approximately 3% over the past week and off nearly 10.6% across the last four weeks. This recent weakness has left shares more than 20% below their 52-week high of $110.68 set in July. Observers continue to monitor trading patterns ahead of the upcoming earnings report in late November. The recent price action underscores a cautious investor sentiment amid heightened regulatory pressure. Market data shows the latest close and trend context. 

Meanwhile, CVS Health’s pharmacy benefit manager arm, Caremark, is under intensified scrutiny following a civil investigative demand issued by the Florida Attorney General on June 23, 2026. The probe targets allegations around patient steering, differential reimbursement rates favoring CVS-owned pharmacies, restrictive audits of independents, and opaque contracting and rebate arrangements. The AG demanded documents and testimony by July 28, though extensions are not unusual in such investigations.

These Florida-level inquiries are part of a larger regulatory environment targeting PBM practices nationwide. Federal guidance and enforcement—highlighted by FTC settlements and proposed legislation—are increasingly focused on transparency and fair pharmacy competition, placing CVS and other integrated PBMs at the center of industry reform efforts.

Stock at a Crossroads Amid Regulatory Uncertainty

CVS stock’s short-term weakness contrasts with earlier stability. In the week ending October 2, weekly equity reports show a 3% decline, following a more significant 10.6% drop over the previous four weeks. On the twelve-week horizon through early October, shares lost about 19.05%, moving down from the $106 range to the current price level. Trend indicators remain neutral to negative, though historical patterns suggest modest upside potential in the near term. With earnings approaching, investor attention is squarely on how CVS will address regulatory headwinds and whether the company’s core businesses can stabilize.

What Comes Next

Florida’s investigative probe could evolve into a formal lawsuit or lead to settlement terms, potentially affecting Caremark’s operating practices or incurring fines. For investors, the key milestones include disclosures in the upcoming earnings report and any material updates tied to PBM regulation. Absent fresh catalysts, CVS stock may continue to track broader healthcare sentiment and regulatory developments. Stakeholders should watch for new filings, enforcement actions in other states, or federal policy shifts that influence PBM oversight.

As CVS navigates these challenges, its stock performance reflects a market weighing both persistent regulatory risk around Caremark and the company’s broader turnaround strategy across health services and insurance operations.